Generic Name and Formulations:
Bimatoprost 0.01%, 0.03%; oph soln; contains benzalkonium chloride.
Indications for LUMIGAN:
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
≥16yrs: 1 drop once daily in the PM.
<16yrs: not recommended.
Do not exceed recommended dose. Renal or hepatic impairment. Ocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Allow at least 5 minutes between application of other topical ophthalmic agents.
Conjunctival hyperemia, eyelash growth, ocular itching or dryness, visual disturbances, foreign body sensation, other local effects, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, blepharitis, cataract, keratitis, photophobia, infection, headache, abnormal liver function tests, asthenia, hirsutism.
Soln—2.5mL, 5mL, 7.5mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC